Pharma Focus America

GEn1E Lifesciences Adds NextGen Selective Immunomodulator Target to Portfolio, Broadens Pipeline

Wednesday, July 27, 2022

GenScript ProBio, a global Contract Development and Manufacturing Organization (CDMO), and DAAN Bio Therapeutics, an innovative drug developer specializing in antibody treatments and cell therapy drugs, have announced a strategic cooperation Memorandum of Understanding (MOU) for the advancement of innovative drug discovery and development. The MOU aims to enhance collaboration between GenScript ProBio and DAAN in the field of cell and gene therapy (CGT) and biologics.

Under this agreement, the two companies will strategically collaborate throughout the entire development process, encompassing discovery, manufacturing, and clinical trials of antibody and cell treatments, as well as related research and service projects.

DAAN Bio Therapeutics, in conjunction with the DAAN Cancer Research Institute and Yonsei New Il Han Institute for Integrative Cancer Research, has conducted single-cell transcriptomic and proteomic biomarker analysis using tissues obtained from solid cancer patients. Consequently, DAAN Bio Therapeutics has engaged GenScript ProBio as a Contract Manufacturing Organization (CMO) to develop antibodies that specifically target the identified materials. Additionally, DAAN Bio Therapeutics has established its own pipeline for the production of bispecific antibodies using antibodies derived through Good Manufacturing Practice (GMP) production.

Brian H. Min, CEO of GenScript ProBio, expressed his optimism, stating, "I believe that this strategic partnership with DAAN Bio Therapeutics will provide significant support as a global partner in accelerating the development of DAAN's antibody and cell therapy through GenScript ProBio's comprehensive CDMO service platform."

Byoung Chul Cho, Co-Founder & CEO of DAAN Bio Therapeutics, emphasized the value of the collaboration, stating, "This strategic cooperation presents an opportunity to invigorate the development of antibody and cell therapy targeting unique cancer treatment markers identified by DAAN Bio Therapeutics, leveraging GenScript ProBio's qualified and competitive technologies."

Through this strategic partnership, GenScript ProBio and DAAN Bio Therapeutics will intensify their collaboration to further advance DAAN Bio Therapeutics' pipeline, encompassing antibody drugs and cell therapy.

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024